| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701752 | Journal of Thoracic Oncology | 2016 | 34 Pages |
Abstract
In this cohort, approximately 85% of individuals have known driver mutations (EGFR 59.4%, KRAS 7.4%, ALK 7.4%, ERBB2 2.6%, ROS1 2.2%, RET 2.2%, MET 1.8%, BRAF 1.1%, and NRAS 0.4%). Seventy percent of smokers and 90% of nonsmokers had defined oncogenic drivers matching the U.S. Food and Drug Administration-approved targeted therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Shiyong BS, Yoon-La MD, PhD, Zhuolin PhD, Xiao PhD, Maruja BS, Zhengyan PhD, Ensel PhD, Jian PhD, Jason C. PhD, Xiangsheng PhD, Christoph PhD, Xiaoqiao PhD, Yunfei PhD, Wei PhD, Ronghua PhD, Shijun PhD, Gang MD, PhD, Awei MS, Mao MD, PhD,